SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.68 CNY | -0.60% |
|
+7.35% | +19.31% |
| 29/04 | Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 16/04 | Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets | MT |
Strengths
- This company will be of major interest to investors in search of a high dividend stock.
Ratings chart - Surperformance
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +19.31% | 2.18B | - | - | |
| +8.02% | 72.94B | A | ||
| +12.64% | 9.06B | A- | ||
| -10.56% | 5.07B | A- | ||
| +58.79% | 4.78B | - | ||
| +4.07% | 3.9B | B- | ||
| -16.90% | 2.56B | C- | ||
| +21.43% | 2.42B | B | ||
| -26.13% | 2.39B | - | ||
| -0.54% | 1.65B | D+ |
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-
Consensus
Analyst Opinion
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 600420 Stock
- Ratings Shanghai Shyndec Pharmaceutical Co., Ltd.